2017
DOI: 10.1177/1759720x16687481
|View full text |Cite
|
Sign up to set email alerts
|

Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential

Abstract: Biologics have changed expectation and outcomes for rheumatoid arthritis (RA). However, the optimal duration and sequence of therapy for this disease has yet to be determined. Also, a significant number of patients do not satisfactorily respond to currently available therapies. The Janus kinase (JAK) inhibitors represent a new class of therapies for RA. These drugs work uniquely by inhibiting intracellular pathways thought to be important in the pathogenesis of RA. They are available as oral agents, which is a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
0
2

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(31 citation statements)
references
References 11 publications
0
29
0
2
Order By: Relevance
“…The bioavailability of baricitinib upon oral administration is 80% and it reaches a peak plasma concentration within 1 h. the half life of baricitinib is 12.5 h with a volume of distribution of 76 L and its 50% protein binding. It is metabolised in liver by oxidation mediated through CYP3A4 and it is eliminated unchanged from the urine [154]. The main side effects associated with baricitinib are thrombosis, upper respiratory tract infections and malignancy.…”
Section: Baricitinibmentioning
confidence: 99%
“…The bioavailability of baricitinib upon oral administration is 80% and it reaches a peak plasma concentration within 1 h. the half life of baricitinib is 12.5 h with a volume of distribution of 76 L and its 50% protein binding. It is metabolised in liver by oxidation mediated through CYP3A4 and it is eliminated unchanged from the urine [154]. The main side effects associated with baricitinib are thrombosis, upper respiratory tract infections and malignancy.…”
Section: Baricitinibmentioning
confidence: 99%
“…As Baricitinib makes more number of hydrogen bonding interactions and its docking score is more than that of other drugs (Table 1), it may be proposed that the Baricitinib, which is an inhibitor of the JANUS kinase and is used for the treatment of rheumatoid arthritis [37] would serve as a better inhibitor of the RdRp protein than that of Fivapiravir and other nucleobase drugs studied here.…”
Section: Drugmentioning
confidence: 99%
“…It works by blocking the action of histamine, a substance in the body that causes allergic reactions likely to reduce inflammation. [46][47][48][49]. It is being studied as a possible treatment for SARS-CoV-2 due to in vitro evidence supporting its ability to combat this infection.…”
Section: The Restorative Power Of Mscsmentioning
confidence: 99%